(Q36666769)

15 August 2017

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial (English)

1 reference

World Health Organization

15 August 2017

0 references

1 reference

3

Jerzy Holowiecki

1 reference

15 August 2017

Heinz Gisslinger

1

1 reference

15 August 2017

Mirjana Gotic

2

1 reference

15 August 2017

Miroslav Penka

4

1 reference

15 August 2017

Juergen Thiele

5

1 reference

15 August 2017

Hans-Michael Kvasnicka

6

1 reference

15 August 2017

Robert Kralovics

7

1 reference

15 August 2017

Petro E Petrides

8

1 reference

15 August 2017

ANAHYDRET Study Group

9

1 reference

15 August 2017

language of work or name

English

0 references

publication date

11 January 2013

1 reference

15 August 2017

1 reference

15 August 2017

121

1 reference

15 August 2017

10

1 reference

15 August 2017

1720-1728

1 reference

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

European consensus on grading bone marrow fibrosis and assessment of cellularity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Statistical aspects of the analysis of data from retrospective studies of disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Essential thrombocytosis: underemphasized cause of large-vessel thrombosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Neurologic manifestations of essential thrombocythemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Clinical manifestations of essential thrombocythemia in young adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

No treatment for low-risk thrombocythaemia: results from a prospective study.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Nonparametric estimation for the difference or ratio of median failure times.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Evaluation of experiments with adaptive interim analyses.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3591796

Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?

20 October 2018

1 reference

12 December 2020

Pulsatile tinnitus as a first symptom of essential thrombocythemia

1 reference

12 December 2020

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

12 December 2020

Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway

1 reference

12 December 2020

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

12 December 2020

Clinical course of essential thrombocythemia in 147 cases

1 reference

12 December 2020

Combining different phases in the development of medical treatments within a single trial

1 reference

12 December 2020

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

1 reference

12 December 2020

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

1 reference

12 December 2020

The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies

1 reference

12 December 2020

Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients

1 reference

12 December 2020

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis

1 reference

12 December 2020

Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up

1 reference

12 December 2020

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

12 December 2020

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

1 reference

12 December 2020

Value of bone marrow biopsy in the diagnosis of essential thrombocythemia

1 reference

12 December 2020

10.1182/BLOOD-2012-07-443770

Identifiers

DOI

1 reference

release_brf5n4b65jgedgkhwekxv4sd3i

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/brf5n4b65jgedgkhwekxv4sd3i

24 November 2022

mapped directly with Wikidata item

1 reference

15 August 2017

PubMed publication ID

23315161

1 reference